A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants with Thyroid Eye Disease
Description
The purpose of this dose ranging study is to study the efficacy and safety of TOUR006 SC compared with placebo in participants with moderate to severe TED.
Details
Age
Adult
Eligibility
Male and female participants, from 18 to 75 years of age inclusive, with moderate to severe TED.
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Prem Subramanian, MD, PhD
Study ID
Protocol Number: 23-1181
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers